Reporting owner · CIK 0001814238
Hite Christopher
Visual SEC Form 4 history across 1 companies, 7 transactions and 4 filings.
EVP, CHAIREVP & Chairman, PartneringRoyalty Pharma plc
Open-market mix
0%buys
Latest insider transactions
Form 4 filings from available history. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #228928 | RPRX | Hite Christopher | EVPCHAIR | sale10b5-1 | 3.92k | -$23.1M | S | 09/24 | 09/22 |
| #228927 | RPRX | Hite Christopher | EVPCHAIR | sale10b5-1 | 96.0k | -$562M | S | 09/24 | 09/22 |
| #11089 | RPRX | Hite Christopher | EVPCHAIR | gift10b5-1 | 16.8k | $0 | G | 08/19 | 08/19 |
| #11088 | RPRX | Hite Christopher | EVPCHAIR | sale10b5-1 | 100k | -$599M | S | 08/19 | 08/18 |
| #74830 | RPRX | Hite Christopher | EVPCHAIR | grant | 26.6k | $0 | A | 02/13 | 02/11 |
| #131390 | RPRX | Hite Christopher | EVPCHAIR | C | 30.0k | $0 | C | 02/18/2025 | 02/14/2025 |
| #131389 | RPRX | Hite Christopher | EVPCHAIR | C | 300k | $0 | C | 02/18/2025 | 02/14/2025 |
Latest Form 4 facts
Quick context from source filings
Latest buy
No open-market insider purchase is available.
Open-market buy performance
90-day forward return on this insider's open-market purchases
Forward return is not available yet
We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.
Disclosed ownership
How reported shareholdings evolved
Non-derivative shares held after reported transactions—not stock prices or a complete portfolio.
5 observations · Feb 14, 2025 – Sep 22, 2026. Window ends at the latest available report, not today.
Selected observation · Sep 22, 2026270,401 shares reported
Inspect transaction View exact observations and source transactions
| Transaction date | Shares held after | Filed | Source |
|---|---|---|---|
| Feb 14, 2025 | 600,000 | Feb 18, 2025 | View transaction |
| Feb 11, 2026 | 685,136 | Feb 13, 2026 | View transaction |
| Aug 18, 2026 | 370,401 | Aug 19, 2026 | View transaction |
| Sep 22, 2026 | 274,328 | Sep 24, 2026 | View transaction |
| Sep 22, 2026 | 270,401 | Sep 24, 2026 | View transaction |
Securities and direct/indirect ownership contexts are kept separate and never summed. Joint filings may associate the same disclosed row with multiple owners. Unknown values are omitted, not treated as zero. Lines connect observations for readability; they do not establish holdings between filings, cost basis, or current ownership. Amendments and stock splits require reviewing the source.
Monthly open-market activity
Reported purchase and sale transaction counts
Buys Sells
Net value flow
Buys minus sells
Feb 25
$0
Feb 26
$0
Aug 26
−$6M
Sep 26
−$5.9M
Transaction texture
Ownership and ticket size
Average P/S size$4M
Median P/S size$5.6M
Direct1
Indirect6
Sep 22, 2026sale
Filing-only signals
Deterministic matches in this insider's history
Associated companies
Visual map of known reporting history
Hite Christopher Insider Activity FAQ
SEC Form 4 context
Who is Hite Christopher?
Hite Christopher is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001814238.
Which companies has Hite Christopher reported transactions for?
Royalty Pharma plc
When was Hite Christopher's latest insider buy?
No open-market insider purchase is available for this period.
When was Hite Christopher's latest insider sale?
sale at Royalty Pharma plc on Sep 22, 2026 valued at $231,403.
Where can I see the original SEC filings?
Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.
Are performance metrics included?
This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.